Human Menopausal Gonadotropin (hMG) 75 IU Lyophilized Reagent⁠

£41.99

✓ Fully Standardized 75 IU
✓ Dual-Action Glycoprotein
✓ UK Stocked

Premium laboratory-grade Human Menopausal Gonadotropin (hMG) in a standardized 75 IU configuration. This highly complex, extract-derived biological substance features a balanced 1:1 ratio of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) activity. Structured specifically for optimal visual display and text contrast on your storefront layout, this lyophilized compound serves as a critical model for analyzing dual-receptor signaling mechanics, simultaneous follicular/Sertoli cell activation, and complex steroidogenesis cascades. For laboratory and in vitro research use only. Not for human consumption. Not a medicine.

Human Menopausal Gonadotropin (hMG) | Balanced FSH & LH Dual Reagent

Human Menopausal Gonadotropin (hMG), also scientifically designated as menotropin, is a highly complex biological combination reagent derived from natural mammalian sources. Unlike singular isolated or synthetic peptides, hMG naturally provides equal quantitative balances of both Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) cellular activity, quantified at precisely 75 International Units (IU) per vial.

In the context of preclinical endocrine axis assessment, hMG offers an essential, multi-dimensional reference profile. Because it houses both crucial gonadotropins, it allows laboratory investigators to study the simultaneous, synergistic activation of distinct cellular sub-populations—such as the concurrent stimulation of Granulosa and Theca cells in female modeling, or Sertoli and Leydig cells in male modeling—within a single experimental matrix.

Experimental Dual-Vector Research Context

Preclinical assay models deploying hMG 75 IU are commonly geared toward evaluating the following biochemical parameters:

  • Co-Activation Signaling Cascades: Mapping out the parallel activation of the FSH receptor (FSHR) and Luteinizing Hormone receptor (LHCGR), observing the subsequent downstream cyclic AMP (cAMP) and intracellular calcium ($Ca^{2+}$) response dynamics.
  • Synergistic Steroidogenesis: Investigating the “two-cell, two-gonadotropin” framework to measure how cellular interactions optimize the conversion of androgens into estrogens.
  • Gamete Maturation Pathways: Observing the underlying cellular and structural mechanics involved in germ-cell proliferation, fluid balance adjustments, and healthy tissue development in vitro.

Reagent Specifications & Profile

Chemical Name: Human Menopausal Gonadotropin / Menotropins
Active Hormone Components: Follicle-Stimulating Hormone (FSH) & Luteinizing Hormone (LH)
Potency Calibration: 75 IU FSH activity + 75 IU LH activity per vial
Structure Type: Heterodimeric Glycoprotein Complex Mixture
CAS Registry Number: 61489-71-2
Physical Presentation: Sterile, freeze-dried white uniform lyophilized powder cake under negative pressure

Laboratory Reconstitution & Storage Standards

Because complex glycoprotein molecules contain intricate tertiary protein folding states that are vulnerable to degradation:

  • Long-Term Stabilization: Store unopened, sealed glass vials long-term exclusively inside a laboratory freezer set to -20°C. Protect the vial assembly from constant moisture fluctuations and direct UV exposure.
  • Fluid Integration Protocol: Allow the vacuum-packed vial to fully adapt to local room temperature variables before opening. Reconstitute slowly using Sterile Bacteriostatic Water or standard laboratory saline. Never shake or aggressively vortex the vial, as high fluid shear stress will foam and denature the delicate glycoprotein matrices. Gently roll or swirl until fully dissolved.
  • Liquid Phase Management: Post-dissolution, maintain the fluid media strictly within a dark refrigeration unit between 2°C and 8°C. It is highly recommended to complete all associated testing arrays within 10 to 14 days of reconstitution to avoid structural protein degradation.

⚠️ Preclinical Integrity Notice

All materials documented within this registry are distributed strictly for verified laboratory research, analytical control trials, and foundational in vitro testing models. This compound is not a medicine and is entirely barred from human therapeutic, clinical, veterinary, or diagnostic administration.

Class

Complex Glycoprotein / Gonadotropin Combination Model⁠

Potency

75 IU Follicle-Stimulating Hormone (FSH) + 75 IU Luteinizing Hormone (LH) Activity⁠

Form

Lyophilized Freeze-Dried Solid Powder⁠

Primary Vector

Dual FSHR and LHCGR Receptor Co-Activation⁠